• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.前列腺癌中ERG基因融合产物的拟肽抑制剂的研发
Cancer Cell. 2017 Apr 10;31(4):532-548.e7. doi: 10.1016/j.ccell.2017.02.017. Epub 2017 Mar 23.
2
Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.鉴定一种选择性抑制 ERG 阳性癌细胞生长的小分子。
Cancer Res. 2018 Jul 1;78(13):3659-3671. doi: 10.1158/0008-5472.CAN-17-2949. Epub 2018 Apr 30.
3
Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.靶向前列腺癌中ERG的DNA结合ETS结构域的小分子的发现与表征
Oncotarget. 2017 Jun 27;8(26):42438-42454. doi: 10.18632/oncotarget.17124.
4
Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.TMPRSS2-ERG 与 BAF 染色质重塑复合物的结合介导前列腺癌的发生。
Mol Cell. 2018 Aug 16;71(4):554-566.e7. doi: 10.1016/j.molcel.2018.06.040. Epub 2018 Aug 2.
5
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.ETS 基因融合阳性前列腺癌中抑制聚(ADP-核糖)聚合酶的作用机制。
Cancer Cell. 2011 May 17;19(5):664-78. doi: 10.1016/j.ccr.2011.04.010.
6
Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.转录网络涉及 ERG 和 AR 协调远端同源盒-1 介导的前列腺癌进展。
Nat Commun. 2021 Sep 7;12(1):5325. doi: 10.1038/s41467-021-25623-2.
7
Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.用剪接转换寡核苷酸靶向 ERG 癌基因作为前列腺癌的一种新治疗策略。
Br J Cancer. 2020 Sep;123(6):1024-1032. doi: 10.1038/s41416-020-0951-2. Epub 2020 Jun 25.
8
Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in and -Mutated Prostate Cancer.调控 和 - 突变前列腺癌管腔上皮谱系和抗雄激素敏感性。
Clin Cancer Res. 2018 Sep 15;24(18):4551-4565. doi: 10.1158/1078-0432.CCR-18-0653. Epub 2018 May 29.
9
Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.度他雄胺在 ETS 融合阳性前列腺癌模型中的作用。
Prostate. 2012 Oct 1;72(14):1542-9. doi: 10.1002/pros.22509. Epub 2012 Mar 13.
10
Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer.硝呋齐特通过激活 PARthanatos 克服 TMPRSS2:ERG 融合阳性前列腺癌。
Mol Cancer Ther. 2023 Mar 2;22(3):306-316. doi: 10.1158/1535-7163.MCT-22-0159.

引用本文的文献

1
Peptides derived from the POU domain of BRN2 show antitumor activity against murine melanoma model cells in vitro and in vivo.源自BRN2的POU结构域的肽在体外和体内对小鼠黑色素瘤模型细胞显示出抗肿瘤活性。
Cancer Chemother Pharmacol. 2025 Jul 2;95(1):67. doi: 10.1007/s00280-025-04790-9.
2
The Potential of Peptide-Based Inhibitors in Disrupting Protein-Protein Interactions for Targeted Cancer Therapy.基于肽的抑制剂在破坏蛋白质-蛋白质相互作用以进行靶向癌症治疗中的潜力。
Int J Mol Sci. 2025 Mar 28;26(7):3117. doi: 10.3390/ijms26073117.
3
TMPRSS2::ETS translocation in nonprostatic malignancies: an unexpected finding in thymic carcinoma and pulmonary adenocarcinoma.非前列腺恶性肿瘤中的TMPRSS2::ETS易位:胸腺癌和肺腺癌中的意外发现
Virchows Arch. 2025 Mar;486(3):627-631. doi: 10.1007/s00428-024-03927-0. Epub 2024 Sep 16.
4
EVI1-mediated Programming of Normal and Malignant Hematopoiesis.EVI1介导的正常和恶性造血编程。
Hemasphere. 2023 Oct 4;7(10):e959. doi: 10.1097/HS9.0000000000000959. eCollection 2023 Oct.
5
Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours.聚(ADP-核糖)聚合酶 1(PARP-1)抑制:一种用于 ETS 表达肿瘤的有前途的治疗策略。
Int J Mol Sci. 2023 Aug 30;24(17):13454. doi: 10.3390/ijms241713454.
6
Peptidomimetics in cancer targeting.癌症靶向的肽模拟物。
Mol Med. 2022 Dec 7;28(1):146. doi: 10.1186/s10020-022-00577-3.
7
Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope.非小分子PROTAC(NSM-PROTAC):蛋白质降解万花筒
Acta Pharm Sin B. 2022 Jul;12(7):2990-3005. doi: 10.1016/j.apsb.2022.02.022. Epub 2022 Feb 26.
8
Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.利用人工智能预测前列腺癌中 ERG 基因融合状态。
BMC Cancer. 2022 May 5;22(1):494. doi: 10.1186/s12885-022-09559-4.
9
Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer.靶向ERG融合阳性前列腺癌的过去、当前及未来策略
Cancers (Basel). 2022 Feb 22;14(5):1118. doi: 10.3390/cancers14051118.
10
Systematic illumination of druggable genes in cancer genomes.对癌症基因组中可成药基因的系统性阐释。
Cell Rep. 2022 Feb 22;38(8):110400. doi: 10.1016/j.celrep.2022.110400.

本文引用的文献

1
Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation.TMPRSS2-ERG 融合导致的截短 ERG 癌蛋白可抵抗 SPOP 介导的蛋白酶体降解。
Mol Cell. 2015 Sep 17;59(6):904-16. doi: 10.1016/j.molcel.2015.07.025. Epub 2015 Sep 3.
2
SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.SPOP促进ERG癌蛋白的泛素化和降解以抑制前列腺癌进展。
Mol Cell. 2015 Sep 17;59(6):917-30. doi: 10.1016/j.molcel.2015.07.026. Epub 2015 Sep 3.
3
ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.ERG激活YAP1转录程序并诱导衰老相关前列腺肿瘤的发生。
Cancer Cell. 2015 Jun 8;27(6):797-808. doi: 10.1016/j.ccell.2015.05.005.
4
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.劫持E3泛素连接酶大脑神经酰胺酶以有效靶向BRD4。
Chem Biol. 2015 Jun 18;22(6):755-63. doi: 10.1016/j.chembiol.2015.05.009. Epub 2015 Jun 4.
5
DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.药物研发。邻苯二甲酰亚胺缀合作为体内靶蛋白降解的一种策略。
Science. 2015 Jun 19;348(6241):1376-81. doi: 10.1126/science.aab1433. Epub 2015 May 21.
6
The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer.长链非编码RNA PCAT29抑制前列腺癌的致癌表型。
Mol Cancer Res. 2014 Aug;12(8):1081-7. doi: 10.1158/1541-7786.MCR-14-0257. Epub 2014 Jul 16.
7
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.在去势抵抗性前列腺癌中靶向治疗 BET 溴结构域蛋白。
Nature. 2014 Jun 12;510(7504):278-82. doi: 10.1038/nature13229. Epub 2014 Apr 23.
8
Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.去泛素化酶抑制前列腺癌细胞癌基因转录因子 ERG 的消融作用。
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4251-6. doi: 10.1073/pnas.1322198111. Epub 2014 Mar 3.
9
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features.featureCounts:一个用于将序列读取分配给基因组特征的高效通用程序。
Bioinformatics. 2014 Apr 1;30(7):923-30. doi: 10.1093/bioinformatics/btt656. Epub 2013 Nov 13.
10
Software for computing and annotating genomic ranges.基因组范围计算和注释软件。
PLoS Comput Biol. 2013;9(8):e1003118. doi: 10.1371/journal.pcbi.1003118. Epub 2013 Aug 8.

前列腺癌中ERG基因融合产物的拟肽抑制剂的研发

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.

作者信息

Wang Xiaoju, Qiao Yuanyuan, Asangani Irfan A, Ateeq Bushra, Poliakov Anton, Cieślik Marcin, Pitchiaya Sethuramasundaram, Chakravarthi Balabhadrapatruni V S K, Cao Xuhong, Jing Xiaojun, Wang Cynthia X, Apel Ingrid J, Wang Rui, Tien Jean Ching-Yi, Juckette Kristin M, Yan Wei, Jiang Hui, Wang Shaomeng, Varambally Sooryanarayana, Chinnaiyan Arul M

机构信息

Michigan Center for Translational Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA.

Michigan Center for Translational Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA.

出版信息

Cancer Cell. 2017 Apr 10;31(4):532-548.e7. doi: 10.1016/j.ccell.2017.02.017. Epub 2017 Mar 23.

DOI:10.1016/j.ccell.2017.02.017
PMID:28344039
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5443258/
Abstract

Transcription factors play a key role in the development of diverse cancers, and therapeutically targeting them has remained a challenge. In prostate cancer, the gene encoding the transcription factor ERG is recurrently rearranged and plays a critical role in prostate oncogenesis. Here, we identified a series of peptides that interact specifically with the DNA binding domain of ERG. ERG inhibitory peptides (EIPs) and derived peptidomimetics bound ERG with high affinity and specificity, leading to proteolytic degradation of the ERG protein. The EIPs attenuated ERG-mediated transcription, chromatin recruitment, protein-protein interactions, cell invasion and proliferation, and tumor growth. Thus, peptidomimetic targeting of transcription factor fusion products may provide a promising therapeutic strategy for prostate cancer as well as other malignancies.

摘要

转录因子在多种癌症的发展中起关键作用,针对它们进行治疗性靶向仍然是一项挑战。在前列腺癌中,编码转录因子ERG的基因经常发生重排,并在前列腺肿瘤发生中起关键作用。在此,我们鉴定出了一系列与ERG的DNA结合结构域特异性相互作用的肽。ERG抑制肽(EIPs)及其衍生的拟肽以高亲和力和特异性结合ERG,导致ERG蛋白的蛋白水解降解。EIPs减弱了ERG介导的转录、染色质募集、蛋白质-蛋白质相互作用、细胞侵袭和增殖以及肿瘤生长。因此,对转录因子融合产物进行拟肽靶向可能为前列腺癌以及其他恶性肿瘤提供一种有前景的治疗策略。